Core Viewpoint - The article discusses the challenges and strategic shifts faced by Boya Biological, a blood product platform under China Resources, as it navigates a downturn in the blood product industry while seeking to establish itself as a leader in the sector. Group 1: Management Changes - Boya Biological has experienced significant management changes, including the resignation of President Ren Hui after less than a year, reflecting the company's response to industry pressures and the need for a leadership capable of navigating through challenging times [2][19]. - The management transitions at both Tian Tan Biological and Boya Biological are seen as attempts to reconstruct growth logic amid a collective industry downturn [2][19]. Group 2: Business Development Phases - Boya Biological's development can be divided into three phases: initial stabilization post-acquisition by China Resources, a phase of asset divestiture to refocus on core blood products, and a current phase of aggressive expansion through acquisitions [3][21][24]. - The company has been actively divesting non-core assets from 2023 to 2025, resulting in a significant drop in net profit but increasing the proportion of revenue from blood products, which is viewed positively by the market [6][21]. Group 3: Acquisition Strategy - In July 2024, Boya Biological acquired 100% of Green Cross Hong Kong for 1.82 billion yuan, gaining access to several key blood product varieties and expanding its plasma collection network [9][24]. - The acquisition is part of Boya's strategy to enhance its market position and scale in the blood product industry, which is critical for competing with industry leaders [7][22]. Group 4: Financial Performance - Boya Biological's financial outlook for 2025 indicates a projected revenue increase of 10%-25% to between 1.908 billion and 2.169 billion yuan, but a significant decline in net profit by 65.62%-73.55% is expected, highlighting the "growth without profit" dilemma [14][29]. - The company faces challenges from industry-wide pressures such as centralized procurement, DRG/DIP reforms, and increased competition, which have led to a decrease in gross margins for blood products [17][31]. Group 5: Research and Development - Boya Biological is expanding its product pipeline, with new products like a high-concentration immunoglobulin approved for market release, which is expected to enhance its product offerings and improve plasma utilization [14][30]. - The company is also investing in R&D, with a reported expenditure of 44.72 million yuan in the first half of 2025, representing 4.44% of its revenue, to support the development of new therapies and expand its product range [16][31].

Core Viewpoint - The company is making steady progress on its C1 esterase inhibitor research project and aims to enhance its product structure and core competitiveness through increased R&D efforts [1] Summary by Categories R&D Progress - The C1 esterase inhibitor is progressing smoothly according to the company's statement on the investor interaction platform [1] - The company plans to accelerate the new product launch process as part of its strategy to broaden its product structure [1] Future Expectations - The company acknowledges that the development and approval of new products is a lengthy and high-risk process, indicating that there are uncertainties involved [1] - The company will provide timely updates based on the progress of product development [1]

Group 1: Business Strategy and Focus - The company has determined to focus on the development of blood products and aims to become a world-class enterprise in this field, with plans to dispose of or divest non-blood product businesses as necessary [2][3] - The company is actively applying for new plasma stations in eligible regions to seize opportunities in the "14th Five-Year Plan" for blood product industry development [2][3] Group 2: Operational Goals and Management - The company is enhancing its plasma station operational management and aims for continuous improvement through organizational restructuring and digital empowerment [3] - The management model involves three business centers with vertical penetration of functions to strengthen integration and improve profitability [3][4] Group 3: Product Development and Market Expansion - The company is committed to an internationalization strategy that includes drug international registration and the introduction of innovative products and advanced technologies [3] - New products such as IVIG (10%) and Tetanus Immunoglobulin are expected to be launched in 2025, while C1 Esterase Inhibitor is anticipated to be available by 2027 [4] Group 4: Market Performance - The company’s PCC market share ranks third in the industry, with significant sales achievements in the chronic disease management project for 2024 [4]